FAP and neoplasm: Umaña and colleagues have reported on multiple not-alpha IL-2 fusions (IL-2v) that aim at localizing IL-2 at the target tumor site employing CEA (cergutuzumab amunaleukin; ref. 49) and FAP (simlukafusp alfa; ref. 50) engagement arms on the IgG construct.